SFPM(SZ:002737) Shen Zhen Shang Bao·2025-07-11 06:59Core Viewpoint - The frequent changes in the executive team of Kew Flower Pharmaceutical may indicate a strategic shift aimed at improving the company's marketing system and overall performance, especially in light of recent poor financial results [1][3]. Group 1: Executive Changes - Vice General Manager Chen Liang resigned for personal reasons and will no longer hold any positions within the company or its subsidiaries [1]. - The company has seen multiple executive departures, including Vice General Manager Ma Xingsheng due to retirement, and two others, Li Jinming and Zhu Xiaonan, also leaving for retirement and personal reasons respectively [1]. - Kew Flower Pharmaceutical has appointed three new executives since 2025, including professional manager Xiao Lin as Vice General Manager [1][2]. Group 2: Financial Performance - Kew Flower Pharmaceutical reported its worst performance since 2018, with a revenue of 3.377 billion yuan in 2024, a decrease of 40.76% year-on-year [3]. - The net profit attributable to shareholders fell to 492 million yuan, down 56.03% compared to the previous year, with a basic earnings per share of 0.84 yuan [3]. - In the first quarter of 2025, the downward trend continued, with revenue of 663 million yuan, a year-on-year decline of 56.30%, and a net profit of 57.11 million yuan, down 77.62% [3].